The in vitro gut model is an invaluable research tool to study indigenous gut microbiota communities, the behaviour of pathogenic organisms and the therapeutic and adverse effect of antimicrobial administration on these communities. The model has been validated against the intestinal contents of sudden death victims to reflect the physicochemical and microbiological conditions of the proximal to distal colon, and has been extensively used to investigate the interplay between gut microbiota populations, antibiotic exposure and Clostridium difficile infection. More recently the gut model has been adapted to additionally model intestinal biofilm. Here we describe the structure, assembly and application of the biofilm gut model. Key words: Chemostat, Clostridium difficile, biofilm, modelling, mucosa, microbiota,
Introduction
Clostridium difficile infection (CDI) continues to pose a major public health threat and is associated with significant patient morbidity and mortality. Recurrent disease is observed in ~20% of patients [1] , which introduces difficulties in treatment management and places further burden on healthcare facilities. The pathophysiological mechanisms of recurrent CDI are not fully understood, but likely involve continued disruption of the host gut microbiota, persistence of C. difficile spores and inadequate host immune response.
The human colon is a highly complex and diverse ecosystem comprising planktonic communities and sessile bacteria within mucosal biofilms. Biofilms are associated with 65% of nosocomial infectious in the US [2] with treatment costs over $1 billion annually [3, 4] .
Studies on intestinal mucosal communities are limited due to the physical inaccessibility of the healthy gut; therefore little is known about intestinal biofilms. Sessile communities differ from their planktonic counterparts, most notably in terms of recalcitrance to therapeutic interventions. The mucosal biofilm and the behaviour of C. difficile within this biofilm is likely to be of key importance in the disease progression, but is poorly understood.
The importance of investigating the behaviour of C. difficile within biofilm has recently been recognised by numerous research groups. However, initial studies utilise simple in vitro systems focused on single or dual species biofilms, which cannot accurately simulate the complex bacterial communities and environment of the human colon. Investigation of C.
difficile biofilms is hampered by the same constraints as investigation of C. difficile planktonic cultures; namely that behaviour in simplified laboratory conditions is markedly different from behaviour in the complex, multi-species environment of the colon. Like other areas of C. difficile research, investigation of mucosa-associated C. difficile communities has utilised a murine model of CDI. However, animal models of CDI, including the hamster and mouse model, are limited by their inability to accurately reflect conditions within humans, and possess an intestinal physiology and microbiome which differs markedly from humans.
We have previously reported the use of an in vitro model of the human colon, which is validated against the intestinal contents of sudden death victims [5] . This model has been successfully utilised to determine the propensity of antimicrobial agents to induce CDI, efficacy of CDI treatment therapies and the effect of these antimicrobial agents upon C.
difficile and the indigenous gut microbiota. It is reflective of disease in vivo and correlates well with clinical findings, thus providing an excellent research tool. This model has recently been adapted to study the formation and roles of complex, mixed-species intestinal biofilms, by incorporating 18 removable glass rods into vessel 3 (representing the distal colon and of most physiological relevance to CDI), which promote formation and subsequent sampling and analysis of intestinal biofilm [6] . The biofilm model has been validated for reproducible and consistent formation of mixed-species intestinal biofilms. Optimal biofilm formation and removal techniques have been determined. The biofilm gut model is currently the only in vitro platform enabling analysis of complex, multi-species intestinal biofilm and has previously been utilised to analyse sessile mixed-species communities and investigate the role of biofilms in CDI [7] . We describe here the structure, the assembly and application of the traditional gut model, and how this model can be adapted to additional allow the analysis of intestinal biofilm communities. b. A gas inlet consisting of glass gas delivery tube, which allows the delivery of nitrogen gas into the culture fluid of the vessel.
c. A gas outlet to allow gas to escape from the vessel. Both the gas inlet and gas outlet ports are connected to a 0.22 µm vent filter.
d. A pH probe (attached to a pH control unit) attachment allowing the probe to be inserted into the vessel contents.
e. A triple-pronged media feeder (central port), which delivers growth media (or the contents from an upstream vessel), acid or alkali (via autoclaved tubing attached to an automated pH control unit). or similar) able to achieve a flow rate of 13.2mL/h (see Note 5). 7 . Waste: The overflow from vessel 3 flows to an autoclavable waste vessel.
Biofilm chemostat vessel
1. Biofilm chemostat vessel (Soham Scientific, Ely, UK): The biofilm vessel replaces vessel 3 and has a 300 mL working volume, lid, attachments as outlined above (gas inlet changed to a circular pipe, with drilled holes interspersed on the surface to encourage even distribution of gas flow across the rods) and 18 rod attachment ports. The ports for the biofilm vessel attachments are smaller (B14) to allow for rod attachments.
2. Biofilm rods: Ground glass rods (2mm diameter) are inserted through the lid screwed in place. Upon removal of rods, replacement screw caps are placed onto the lid to maintain the integrity of the system.
Growth medium
The model is top fed with a complex growth medium that is prepared in 2L volumes;
constituents are listed in difficile should be discarded. Faecal emulsion is prepared by suspending 10% w/v C. difficilenegative faeces in pre-reduced PBS, and the suspension emulsified in a stomacher until a smooth slurry is formed. Any large particulate matter is removed by filtration through a sterile muslin cloth.
C. difficile spore preparation
C. difficile is inoculated onto a single CCEYL plate and incubated anaerobically at 37°C for 48
hours. All growth is removed and sub cultured onto 10 Columbia blood agar (CBA) plates and incubated anaerobically at 37°C for 10-14 days. All growth is removed and emulsified into 1 mL of sterile saline, to which 1 mL of 99.6% ethanol is added. The suspension is vortexed for 30 seconds and stored aerobically at room temperature. 
Biofilm analysis
Biofilm associated bacterial populations are enumerated following careful removal of rods from the biofilm model. Rods are transferred into 5 mL pre-reduced saline, thoroughly vortexed for 2 mins and the rod discarded. Re-suspended biofilm is centrifuged at 4000 rpm for 10 mins, the supernatant removed and pellet re-suspended in 2 mL pre-reduced saline.
An aliquot (500 µL) is centrifuged and stored at 4 C for cytotoxin assay. A second aliquot (1 mL) is transferred to a pre-weighed eppendorf, centrifuged at 16000 g for 15 minutes and supernatant discarded. The remaining pellet is weighed and pellet weight calculated by subtracting the eppendorf weight from the total. The remaining biofilm suspension is enumerated as described for planktonic organisms and units were reported as log10cfu/g of biofilm.
3. Quantification of biofilm-associated antimicrobial activity was determined using the assumption that 1 g of biofilm was equal to 1 mL of planktonic culture fluid.
Experimental design
For a typical gut model experiment 2 triple stage models are constructed and run in parallel.
After the gut models are inoculated with faecal emulsion no further interventions are made for 14 days to allow the system to equilibrate (Fig. 3, period A 4. pH probes must be able to withstand high protein concentrations.
5. Growth media and growth media tubing can become contaminated. The resazurin indicator in the media may cause a colour change (red to yellow) if this occurs.
6. Resazurin must be delivered into the medium whilst still warm ( C 7. Steady State (Period A) can be flexible in length, and should last until microflora populations are stable. Typically this will be ~10-14 days, but can be extended if required.
8. Clindamycin instillation results in consistent CDI induction in the gut model and is therefore the agent of choice for CDI induction during experiments focussing on CDI treatment. Clindamycin is instilled to achieve levels equivalent to those in bile [8] .
9. Vancomycin is the first line treatment agent for CDI and used as a comparator agent to determine superiority/non-inferiority/inferiority of novel anti-CDI agents under investigation.
10. Glucose is unstable at excessive temperatures. Medium constituents, including glucose should be added to cooled, autoclaved distilled water and steamed (100° C) until molten.
Once cooled (approx. 50° C) propionic acid should be added and pH adjusted using 10M NaOH and/or 10M HCl.
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